We studied the expression of cell surface antigens associated with myeloid and lymphoid leukemias on bone marrowderived blast cells from 339 patients with newly diagnosed de novo acute myeloid leukemia (AML) enrolled on Cancer and Leukemia Group B (CALGB) chemotherapy protocols. Surprisingly, of 211 cases studied for the expression of CD2 (T-cell marker, sheep erythrocyte binding receptor for T lymphocytes) 45 were positive (21%). In addition, of 298 patients studied for CD19 (B-lymphocyte marker), 41 were positive (14%). Overall, of 170 patients studied for both CD2 and CD19, 56 (33%) were positive. Interestingly, central review of the French-American-British (FAB) morphology of the CD2-and CD19-positive cases showed that FAB M3 was twice as frequent, and M4E eight times as frequent compared with the CD2-and CD19-negative cases. Of 22 lymphocyte antigen-positive cases in which cells were available for studies of lg or T-cell antigen receptor (TCR) gene rearrangement, 20 were germline, one had a rearranged lg heavy chain gene, and one had rearranged TCRp and lg heavy chain genes. The presence of messenger RNA for CD2 was demonstrated in four CD2 surface antigen-positive cases, thus validating the cell surface data. Lymphocyte antigen-positive cases had karyotypes commonly seen in AML; 71% of cases with an abnormal clone had t(8;21)(q22;q22), inversion
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HETREATMENT OF acute myeloid leukemia (AML)
T has improved steadily over the past 10 years.' Sixty to seventy percent of patients achieve a complete remission (CR) after induction therapy, which usually includes cytosine arabinoside (ARA-C) and daunorubicin.' Unfortunately, up to 75% of these patients eventually relapse and ultimately die of their disease. However, approximately 15% to 20% of patients enjoy prolonged disease-free survival and it is assumed that many of these patients are cured of their disease.
Considerable effort has been spent in identifying prognostic variables that might predict how patients will fare with therapy. Groups of patients stratified by examination of morphology, cytogenetics, and surface antigens have been identified and associated with response to therapy and s u r~i v a l .~~~ Numerous independent prognostic variables have thus been identified for patients with AML. However, no single variable can accurately predict prognosis.
The Cancer and Leukemia Group B (CALGB) began a prospective study of the expression of surface antigens 16(p13q22) , t(15;17)(q22;q12), or t(9;11)(p22;q23). The patients with lymphocyte markers had a significantly higher incidence of these karyotypic abnormalities compared with patients with lymphocyte antigen-negative AML (34% w 15%. P < .02). When the outcome t o therapy of the lymphocyte antigen-positive cases was compared with that for the CD2, CD19-negative cases, we found that the CD2, CD19-positive cases actually had higher complete remission rates (75% w 59%,P = .04), and significantly longer time t o failure (P = .02; 32.4% ? 6.0% Y 18.0% ? 4.1% at 2 years) and overall survival (P = .02; 43.5% % 6.3% ~2 6 . 0 % ? 4.5% at 2 years). CD2
antigen-positive cases also had a significantly superior survival (P = .02; 43.8% .+ 7.9% Y 29.8% .+ 3.8% at 2 years).
There were no significant differences (P 5 .05) between the two groups in age, leukocyte count at diagnosis, incidence of extramedullary disease, or FAB classification. Taken together, these findings indicate that a significant proportion of adults with AML have blasts that express lymphoid cellassociated antigens (CD2 and CD19) in the absence of other features of lymphocytic leukemia and that patients whose cells manifest this phenotype have a more favorable prognosis.
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defined by monoclonal antibodies (MoAbs) on AML cells in 1982. An interim analysis of 196 patients showed that there were certain immunologically defined subgroups that had a better prognosis, or alternatively, worse prognosis, based on the expression of several myeloid antigens4 This study continued with the addition of several additional MoAbs. During a recent updated analysis of 339 evaluable patients, we noticed that a high proportion of patients expressed lymphocyte-associated surface antigens on cells classified as AML.' This report describes the morphologic, immunologic, cytogenetic, molecular genetic, and clinical features of these lymphocyte marker-positive AML patients. Surprisingly, we have found that this subgroup of patients survived longer than patients whose blast cells lacked lymphocyte antigens on their cell surfaces.
MATERIALS AND METHODS
Patients. All patients in this study were newly diagnosed adults (age z 16 years) with de novo AML (except for 14 patients with an antecedent hematologic disorder) who were treated on CALGB protocols from 1982 until June 1,1988. After informed consent had been obtained, a sample of heparinized bone marrow and peripheral blood (if the percentage of blasts in the peripheral blood was greater than 50%) was sent by overnight express mail to the CALGB reference immunophenotyping laboratory. From 1982 until September 1986, the laboratory was that of James D. Griffin at the Dana Farber Cancer Institute, Boston, MA. After September 1986, the reference laboratory was that of Edward D. Ball at the Dartmouth Medical School, Hanover, NH. Samples of bone marrow from 339 patients were evaluated for surface markers in this study.
Unstained smears of bone marrow were sent to the central CALGB morphology laboratory at the Morphology and cytochemistry. NY, where the diagnosis of AML was confirmed using WrightGiemsa and cytochemical stains. The morphologic classification was based on the criteria established by the French-AmericanBritish (FAB) Cooperative Study Group.6 At least a 500-cell differential count of the bone marrow slides were performed in all cases. Cytochemical stains included myeloperoxidase, Sudan black B, ASD-chloroacetate esterase combined with a-naphthyl butyrate esterase, and a-naphthyl acetate esterase with sodium fluoride inhibition according to standard methods.' Any case meeting the FAB criteria for lymphocytic leukemia was excluded from this analysis?
All patients were treated according to CALGB protocols for AML, which usually included a standard remission induction regimen of ARA-C and daunorubicin (DNR). Two hundred and forty-eight patients were treated on the CALGB 8221 and 8525 protocols (DNR 45 mglm'id x 3d [30 mg/m' for patients > 60 years of age], ARA-C 200 mg/m2/d x 7d).9 After attaining CR, patients were then randomized to four courses of low, mid, or high-dose ARA-C as postremission intensification therapy, followed by four courses of DNR and subcutaneous ARA-C. Sixty-five patients were treated on protocol 8321, which used ARA-C/DNR induction and a five-drug postinduction program for 8 months." Twenty-one patients were induced into CR with either ARA-Uasparaginase (n = 14) or ARA-Cimitoxantrone (n = 7) followed by postinduction therapy with ARA-C, with or without DNR. Leukemia cells were isolated by Ficoll-Hypaque gradient centrifugation as previously described." The cells were then frozen at 1°C per minute in medium RPMI 1640 (GIBCO, Grand Island, NY) containing 50% fetal bovine serum (Hyclone, Logan, UT) and 10% dimethyl sulfoxide (DMSO; Sigma Chemical Co, St Louis, MO) using a controlled rate freezer, and then stored in liquid nitrogen.
MoAbs. A panel of MoAbs was designed to include those reactive with commonly expressed myeloid cell-associated antigens (CDllb, CD13, CD14, CD15, CD16, CD32, CD33, and CD64), lymphoid cell-associated antigens (CD2, CD5, CD10, and CD19), megakaryocyte-associated antigen (CD41), glycophorin A-associ-
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Cells.
ated antigen (no CD yet assigned), and antigens associated with both myeloid and lymphoid cells (CD34 and HLA-DR) ( CALLA, common acute lymphoblastic leukemia antigen.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From 2-amino-ethylisothiouronium bromide (AET; 140 mmol/L, pH 9) for 15 minutes at 37°C. After washing, the erythrocytes were added to a suspension of AML cells at a ratio of 1 AML cell to 50 erythrocytes, incubated for 15 minutes, and centrifuged for 10 minutes at 300g. Cells in the pellet were gently transferred into 6-well plates, incubated overnight at 4"C, and then transferred to slides for viewing or staining.
All cytogenetic studies were performed as part of a CALGB prospective study of chromosome analysis in acute leukemia (CALGB 8461). Banded chromosome studies of bone marrow obtained at diagnosis were performed in CALGB institutional cytogenetic laboratories and the karyotypes were centrally reviewed. Specimens were processed using primarily short-term (24-to 72-hour) unstimulated cultures. 65°C for 30 minutes in 0.1X SSC, 0.5% sodium dodecyl sulfate (SDS), 0.2 moliL Tris, pH 8.0, the membranes were prehybridized at 42°C for 2 hours in mixtures containing 50% formamide, 10% dextran sulfate, 1 moliL sodium chloride, 0.1 mol/L Tris, pH 7.5,5 mmoVL EDTA, 0.5 m g i " heparin, 0.1% sodium pyrophosphate, 0.5% sarcosyl, and 0.1 mg/mL sonicated salmon sperm DNA. DNA probes labeled with "P to a specific activity of 2 to 3 x lo9 cpmipg by random primer exten~ion'~ were added to the mixtures (1 x lo6 cpmiml) and hybridized for 16 to 18 hours at 42°C. Following a wash in 2X SSC (25°C) for 15 minutes and two washes in 0.1X SSC, 0.2% SDS (65°C) for 30 minutes, the membranes were blotted dry and exposed to x-ray film with an intensifying screen for 3 to 7 days.
The following probes were used: JH, germline Mu gene, 2.5-kb Sau3NSau3A fragment"; C-K, germline K gene, 2.5-kb EcoRIi EcoRI fragmenP4; and Ch germline A gene, 3.8-kb EcoRIIHindIII fragmenP were obtained from Dr Philip Leder (Harvard University, Boston, MA). T-cr Jurkat cDNA, ~Y 1 . 4~~; T-P Jurkat cDNA, 770-bp Pst IiPst I fragment3'; and T-y Jyl, 800-bp HindIIIiEcoRI fragment'* were obtained from Dr Tak Mak (University of Toronto, Canada). T-6 J61, 1.6-kb Xba IiXba I fragment39 was obtained from Dr Stanley Korsmeyer (Washington University, St Louis, MO). These fragments were cut from their vectors and gel-purified before labeling.
Glyoxylated-total cellular RNA from cryopreserved AML cells (20 kg) along with RNA molecular weight markers were electrophoresed in 1% agarose.' The RNA was transferred to nylon filters (Schleicher and Schuell, Kenne, NH) and hybridized to '*P-labeled cDNA probes for 18 hours. The blots were then washed two times with 2X SSC for 5 minutes each at room temperature, once with 0.1X SSC containing 1% SDS at 42°C for 30 minutes, once with 0.1X SSC at room temperature for 5 minutes and then applied to Kodak XAR x-ray film for 48 to 60 hours. Each Northern blot was hybridized with a "P-labeled CD2 cDNA probe (kindly provided by Brian Seed, Boston, subsequently stripped, and rehybridized with the actin probe. The extent of hybridization was quantified by densitometry of autoradiographs using an E-C Apparatus Corp (St Cytogenetic analysis.
Northem analysis of CD2 mRNA expression.
Petersburg, FL) instrument interfaced to a Hewlett-Packard (Palo Alto, CA) integrator. The data were expressed as a ratio of the signal obtained with the CD2 probe divided by the signal obtained with the actin probe to standardize for lane loading.
The primary goal of the statistical analysis performed was to determine whether there are any differences in patient characteristics or outcomes between patients whose marrow blasts express lymphocyte antigens and those whose marrow blasts do not. Survival curves were estimated using the productlimit method.42 Survival curves were estimated from entry onto the treatment protocol, which was also the time the marrow samples were drawn and the patient characteristics recorded. Standard CALGB criteria were used to assess response to therapy. Time to treatment failure was defined for all patients from the date of entry onto treatment protocol until the first of the following events: removal from therapy or failure to respond; relapse for patients who achieved a CR; or death from any cause. Disease-free survival was defined only for patients who achieved a CR and was measured from the date of CR to the date of relapse or death, whichever occurred first. Pvalues are based on the logrank test for su~vival,"~ Fisher's exact test for sex, FAB, extramedullary involvement, and response? and the Wilcoxon test for age, leukocyte count, platelets, and hem~globin.~' Statistical analysis.
RESULTS
Patients.
Three hundred and thirty-nine consecutive patients with evaluable bone marrow specimens were included in this study. The clinical/pathologic features of these patients are shown in Table 2 . Of a subset of 170 cases in which CD2 and CD19 were both evaluable, cells from 56 patients (33%) were found to have the T-lymphocyte marker, CD2, or the B-lymphocyte marker, CD19. An additional 12 cases were studied for only one or the other of CD2 or CD19 and were positive for the marker studied. The 56 patients studied for both antigens and positive for CD2 or CD19 and the 12 patients positive for CD2 or CD19 (when only one marker was studied) were defined as the lymphocyte antigen-positive population. To be considered lymphocyte antigen-negative, patients had to have had both CD2 and CD19 evaluated. One hundred and fourteen patients were in this category. Review of the morphology in the CD2-or CD19-positive cases showed the following distribution: 27 cases were FAB M1 or M2, eight cases were M3, 26 cases were M4 or M5, three were M6, two were acute undifferentiated leukemias, and two were acute unclassifiable leukemia. Interestingly, of 12 patients with M4Eos who could be classified for CD2 and CD19 status in this study, 10 were positive. Table 2 displays these data in contrast to the findings with lymphocyte antigen-negative patients. Although FAB M4Eos was eight times and M3 twice as common among the CD2-or CD19-positive cases compared with CD2-and CD19-negative cases, there was no significant difference overall (P = .08) between the FAE3 subtypes in the two groups. Central review of the morphology of the bone marrow slides submitted from each patient showed that the median percentage of leukemia cells, myeloblasts, promyelocytes, and/or monoblasts was 81% for both lymphocyte antigen-positive and -negative cases. The median percentage of lymphocytes was 3% in both the lymphocyte antigen-positive and -negative cases. tOf the 12 patients classified as M4E whose lymphoid antigen status was evaluable, 10 were lymphoid antigen-positive. the CD2 or CD19 antigens (or both) ( Table 3) . If restricted to only cases in which both markers were studied, the frequency of CD2 or CD19 positivity was 56 cases of 170 (33%). All cases were not studied for each marker because the CD2 MoAb was added to the panel at a later time than the CD19 MoAb.
Zmmnophsnotype. Sixty-eight cases expressed either
CD2, defined by OKT11, was found on 45 of 211 cases (21%), and CD19, defined by MoAb B4 was found on 41 of 298 cases (14%). The median percentages of positive cells for CD2 and CD19, respectively, were 38% and 38% and the ranges were 20% to 85% and 20% to 92%. Of interest, 
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Lymphoid refers to expression of either CD2 or CD19, but not CD13, CD14.CD33, or CD64. Four of the five cases in this category did express CD11 b, and CD15, both of which are myeloid cell-associated but which can also be found on lymphocytic leukemia cells. The FAB subclasses of these four cases are M I (two cases), M2, and M6.
Myeloid refers to expression of either CD13, CD14, CD33, or CD64.
Other myeloid-associated antigens, such as CD1 lb, CD15, and CD16, were also expressed on these cases. two other lymphoid markers (CD5 and CD10) included in the MoAb panel were infrequently positive. CDlO was only found on one case (of 141 studied) and CD5, defined by T101, was found on seven of 238 cases (3%).
Cells from five of the 68 patients (FAB subclasses M1
[n = 21, M2 [n = 11, and M6 [n = 21) that expressed CD2 or CD19 did not express any of several highly myeloid-specific markers including CD13, CD14, CD33, or CD64 (Table 3) . However, four of these cases did express CDllb or CD15, which are both myeloid-cell associated markers. Sixty-three cases expressed both myeloid and lymphoid markers. Seventeen of these cases expressed both CD19 and CD2, while 20 cases were CD2 positive, CD19 negative and 14 cases were CD19 positive, CD2 negative. The remaining 12 lymphocyte antigen-positive cases were classified on the basis of having only one of these markers positive; the other marker was not studied. Studies on stored cells from five cases were found to be negative for cell surface CD3, despite being positive for CD2. To consider whether CD2, CD19 positive cases were those with either an "early" hematopoietic cell (CD34 positive) or larger granular lymphocyte (LGL)/natural killer (NK) phenotype (CD16 positive), the expression of these antigens on CD2-and CDlPpositive cases was analyzed. There were significant correlations between expression of CD34 and both CD2 (P = .04) and CD19 (P = .01) and between CD16 and both CD2 fP=:O4) and CD19 (P = .001). From 122 cases in which all of these markers For personal use only. on October 22, 2017. by guest www.bloodjournal.org From were measured, 10 cases expressed CD34, CD2, and CD19 while seven cases expressed CD34, CD16, and either CD2 or CD19. Two-color flow cytometry was performed on 10 cases that manifested expression of CD33 and CD2 or CD19. In five cases, this analysis was unrevealing because the phycoerythrin-conjugated anti-CD2 MoAb detected CD2 less well than did the original indirect immunofluorescence method used to identify the case. In the other five cases, the two-color analysis showed a subpopulation of cells coexpressing both CD33 and CD2 (three cases) or CD33 and CD19 (two cases). Two representative cases are shown in Fig 1. In Fig lA, a distinct population of cells is seen that co-expressed both CD33 and CD19, while another population of cells expressed only CD33. Displayed in Fig 1B is a case in which essentially all of the cells expressed both CD33 and CD2.
Cells from one patient that expressed high levels of surface CD2 demonstrated an ability to rosette with sheep erythrocytes (data not shown).
Adequate cytogenetic analysis was performed on 178 patients. Of these, CD2 and CD19 status was determined for 129 patients, 44 of whom were CD2-or CD19-positive and 85 of whom were CD2 and CD19-negative (Table 4) . Only normal karyotypes were seen in about 50% of patients in both groups. One-fourth (23%) of the lymphocyte antigen-positive patients had either t(8; 21)(q22;q22) (n = 6) or inversion 16(p13q22) (n = 5). The remaining cases also had clonal chromosome abnormalities associated with Ah4L including t(15;17)(q22;q12) in three cases, and t(9;11)(p22;q23) in one case. The patients with lymphocyte markers had a significantly higher incidence of these markers compared with patients with lymphocyte antigen-negative AML (34% v 15%, P = .02).
Ig and TCR gene rearrangement studies. DNA was extracted from cryopreserved cells from 22 patients in the lymphocyte antigen-positive group. Bone marrow samples were available from 10 patients while only peripheral blood-derived cells were available for study in 12 patients. Gene rearrangements were demonstrated in cells from two Cytogenetics. CDZpositive patients studied and one of the 15 CD19-positive patients studied showed rearrangements of the T-or B-cell-associated genome, respectively. In both cases in which gene rearrangements were identified, the density of the rearranged band(s) compared with the germline band(s) was less than that expected for a leukocyte preparation containing a homogeneous population of myeloblasts representing 73% and 92% (percentages of blasts in the two samples with rearrangements) of the total cells in the sample. This finding suggests that the myeloblast population were not homogeneous and that the gene rearrangements were present in sub-populations of these cells.
Cells from eight patients with Ah4L (four CDZpositive and four CDZnegative) were examined for expression of CD2 mRNA by Northern blotting. The sensitivity of this assay was determined by mixing various percentages of normal lymphocytes with a nonlymphoid cell line, HL-60 (which is CD2-negative) and performing the same experiments. Cells from three of four CDZpositive patients were found to have detectable levels of CD2 mRNA transcripts, levels of which correlated with the degree of cell surface antigen expression as determined by flow cytometry (see Table 5 ). Both 1.65-and 1.3-kb species of mRNA were found in A M L blasts, as has been found in normal T lymphocyte^.^' The lymphocyte mixing experiments indicated that 5% of cells could be normal lymphocytes without being detected by Northern blotting. Thus, it is unlikely that the hybridization observed in the three CD2-positive patients could be attributed to normal lymphocyte contamination in the A M L samples because all of the samples that had detectable CD2 mRNA contained less than 5% lymphocytes (Fig 2) .
Correlations between expression of individual surface markers and clinical parameters were made. Expression of at least one of the lymphocyte antigens, CD2 or CD19, was associated with a higher probability of induction of CR. Lymphocyte antigenpositive and -negative cases had CR rates of 75% and 59%,
Northem analysis.
Response and survival analysis.
For 8 correspond to lanes F, H, G rcspcctivcly (P = .M). Whcn cxamincd by individual markcrs. cxprcssion of CD2 alonc tcndcd to corrclatc with achicvcmcnt of CR; 76% for CD2-positivc caws vcrsus 60% for CD2-ncgativc cases (P = .OX). Exprcssion of CD19 alonc did not corrclatc with achicvcmcnt o f CR (66% v 63% CR ratc for CDIO-positivc I' -ncgativc cascs; P = .73).
Survival of thc cntirc group of lymphocytc antigcnpositivc paticnts was supcrior to thc group of paticnts whosc cclls did not cxprcss thcsc antigcns (P = .02) (Fig  3A) . Onc-and 2-ycar survival for thc lymphocytc antigcnpositivc C~S C S was 61.8% t 5.9% (standard crror) and 43.5% 2 6.3%. Thc corrcsponding figurcs for lymphoid antigcn-ncgativc paticnts wcrc 47.2% 5 4.7% and 26.0% 2 4.5%. rcspcctivcly. Morcovcr. timc to failurc (P = .02) and discasc-frcc survival (P = .08) (paticnts with CR only) wcrc supcrior for thc lymphocytc antigcn-positivc C~S C S (Fig 3B  and C) . Although all survival curvcs wcrc plottcd to 3 ycars, thcrc wcrc scvcral surviving paticnts in cach group bcyond 3 ycars (SCC lcgcnd for Fig 3 for complctc dctails) .
Paticnts whosc cclls wcrc CD2-positivc had a significantly bcttcr survival (P = .02), with 68.9% t 6.9% and 43.8% t 7.9% of paticnts surviving at 1 and 2 ycars ( Fig  3D) . Timc to failurc and discasc-frcc survival also tcndcd to bc supcrior for CD2-positivc paticnts (P = .06 and P = .07, rcspcctivcly) (Fig 3E and F) . One-and 2-ycar Thcrc was n o statistically significant diffcrcncc (P < .OS) bctwccn thc lymphocytc-positivc and -ncgativc paticnts according to agc, SCX, FAB typc. whitc blood ccll count (WBC), platclct count. cxtramcdullary involvcmcnt, or othcr clinical paramctcrs (Tablc 2). Thcrc was a statisticslly significant dificrcncc (P = 3 3 ) bctwccn thc hcmoglobin valucs (at diagnosis) in thc two groups, thc importancc o f which is unknown. Thc impact o n rcsponsc of thc diffcrcnccs in cytogcnctic findings bctwccn lymphocytc antigcnpositivc and -ncgativc paticnts could not bc asscsscd bccausc adcquatc cytogcnctic analyscs wcrc availablc o n only 70% of cascs.
DISCUSSION
Thc purposc of this study was to dctcrminc if thc pattcrn of cxprcssion of surfacc antigcns on AML cclls had prognostic significancc. Thc pancl o f MoAbs choscn was dcsigncd to cncompass thc known mycloid cell-asstxiatcd antigcns and sclcctcd pan-lymphocytc antigcns associatcd with B cclls and T cclls. thc lattcr for thc purposc of cxcluding C~S C S of acutc lymphocytic lcukcmia (ALL). Ovcr a 6-ycar timc pcriod, bonc marrow-dcrivcd blast cclls from 339 paticnts wcrc cxamincd by immunolluorcsccncc with thc pancl of MoAbs. Thc cxprcssion of ccll surfacc antigcns was thcn corrclatcd with rcsponsc to thcrapy, timc to failurc, lcngth of rcmission, and survival. Uncxpcctcdly, wc found that ii large numbcr of cascs that mct thc FAB critcria for AML cxprcsscd T-(CD2) or B-(CDIO) ccllassociatcd antigcns. Morcovcr, as a group, thc paticnts with CD2-or CDIO-positivc lcukcmia cclls had a highcr frcqucncy of rcmission induction, longcr rcmission duration, and survival than thc paticnts without lymphocytc antigcns. Whcn analyzcd scparatcly for CD2 or CD19 cxprcssion, only CD2 cxprcssion corrclatcd with outcomc.
Thc most common Iymphocytc-associatcd antigcn found on AML cclls in this study was thc CD2 antigcn, dcfincd by MoAb OKTl1. This antigcn. known prcviously as thc shccp crythrocytc rcccptor, is found on all maturc T cclls and thc majority of T-ccll malignancics. It has bccn prcviously rcportcd that cclls from somc childrcn with AML also In contrast, the patients in our series have enjoyed a better outcome to standard AML therapy, both in terms of remission induction and survival. The possible reasons for the apparent differences in these studies are numerous and include (1) different patient populations (adult versus children), (2) different treatment regimens, (3) greater statistical power resulting from the larger number of patients in our series, and (4) identification of different patient subsets in the two studies. Mixed phenotypic leukemia can manifest in at least two different ways. There can be two or more distinct cellular subsets with different antigenic phenotypes or there can be one cell population that co-expresses the antigens of both myeloid and lymphocyte cell lineages. Most of the cases identified in this study are probably in the former category based on the following reasoning. Many of our cases (all with very high blast counts) were found to be greater than 90% positive for a myeloid antigen, and simultaneously between 20% and 50% positive for a lymphocyte antigen. This finding suggests that there were blasts that were both myeloid and lymphocyte antigen-positive and, in addition, blast cells that were only myeloid antigen-positive. However, one of the cases studied (Fig 1B) by two-color flow cytometry showed a dominant population that co-expressed both a myeloid and a lymphocyte antigen, thus falling into the latter category.
A B C D E F G H I J
There was an association between lymphocyte antigenpositivity and expression of the hematopoietic progenitor cell antigen, CD34, and the NK cell-associated antigen, CD16. This association implies that many of the cases identified in this study arose from relatively undifferentiated cells (hence, CD34 positivity) or, alternatively, from cells destined to express an NK cell phenotype. Several cases (n = 10) expressed CD34, CD2, and CD19; five of these cases were M1 or undifferentiated (AUL) by FAB classification, implying that the leukemias with this phenotype tend to be morphologically undifferentiated.
Interestingly, five cases that were CDZpositive were found to be CD3-negative. Although expression of both CD2 and CD3 are features of normal T lymphocytes, the For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From lack of detectable CD3, a protein associated with the TCR, suggests that the cells bearing CD2, but not CD3, are not T cells. Thus, our inability to detect TCR rearrangements in 15 of 15 CD2-positive cases studied is not surprising. Therefore, it is not clear that concomitant CD2 and myeloid antigen positivity within a leukemia cell population is an example of a mixed-lineage phenotype. It is possible that CD2-positive AML may reflect an expansion of a normal bone marrow precursor cell that is capable of expressing myeloid antigens and the CD2 antigen. CD2 functions as an adhesion molecule and is believed to be a ligand for the lymphocyte function-associated molecule (LFA-3).48,49 LFA-3 is expressed on all cells, including cytotoxic effector ~ells.4~ It is interesting to speculate that one of the reasons that patients whose cells expressed CD2 had a better outcome might have a biologic basis relating to antileukemia cellular-mediated cytotoxicity stabilized by the expression of CD2.
Relating to the Ig and TCR gene rearrangement studies, there is the possibility that we have underestimated the frequency of rearrangement in lymphocyte antigen-positive AML cells because we were only able to study a small number of the positive cases. Moreover, many cases with high percentages of lymphocyte antigen-positive cells were not studied because cells were not available. However, one case that expressed CD2 on greater than 90% of cells did not have a detectable rearrangement of TCR p-, y-, or &chain genes and was negative for surface expression of CD3, thus suggesting that these cells were not truly T cells by phenotype.
This study demonstrates that cells from patients with AML have yet another level of phenotypic heterogeneity, namely, differential expression of unusual antigens for myeloid cells. That this finding had better, rather than worse, implications for the patients' outcomes to therapy was surprising. Further study is necessary to understand the mechanism by which myeloid leukemia cells express lymphoid cell-associated antigens and why this may be beneficial to the patient.
